From a therapeutic perspective, BCL-2 and Bruton’s tyrosine kinase inhibitors (BTKis) affect the telomere length dynamics in chronic myeloid leukemia (CML). The gene discussed is BCL2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.